{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:57:49Z","timestamp":1794880669691,"version":"4.9.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jpet.2025.103649","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:07:18Z","timestamp":1751454438000},"page":"103649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacodynamic effects of highly selective aldosterone synthase inhibitor vicadrostat in cynomolgus monkeys: Contrasting effects of once versus twice daily dosing"],"prefix":"10.1016","volume":"392","author":[{"given":"Steven M.","family":"Weldon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A.","family":"Cogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5976-3809","authenticated-orcid":false,"given":"Matthew A.","family":"Cerny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosea S.","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina K.","family":"Gueneva-Boucheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly E.","family":"Clifford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Kugler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy G.","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1051-3043","authenticated-orcid":false,"given":"Nicholas F.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jpet.2025.103649_bib1","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States","volume":"30","author":"Murphy","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103649_bib2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.xkme.2019.12.007","article-title":"ACE inhibitor\/angiotensin receptor blocker use patterns in advanced CKD and risk of kidney failure and death","volume":"2","author":"Arora","year":"2020","journal-title":"Kidney Med"},{"issue":"8","key":"10.1016\/j.jpet.2025.103649_bib3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"issue":"4 suppl","key":"10.1016\/j.jpet.2025.103649_bib4","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"23","key":"10.1016\/j.jpet.2025.103649_bib5","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jpet.2025.103649_bib6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"31","key":"10.1016\/j.jpet.2025.103649_bib7","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jpet.2025.103649_bib8","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.jpet.2025.103649_bib9","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jpet.2025.103649_bib10","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/01.HYP.0000259797.48382.b2","article-title":"Nongenomic actions of aldosterone on the renal tubule","volume":"49","author":"Good","year":"2007","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.jpet.2025.103649_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/CS20070123","article-title":"Aldosterone and end-organ damage","volume":"113","author":"Marney","year":"2007","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1016\/j.jpet.2025.103649_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gene.2013.08.047","article-title":"Aldosterone stimulates fibronectin synthesis in renal fibroblasts through mineralocorticoid receptor-dependent and independent mechanisms","volume":"531","author":"Chen","year":"2013","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.jpet.2025.103649_bib13","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/MED.0b013e328360c200","article-title":"Evolving research in nongenomic actions of aldosterone","volume":"20","author":"Williams","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"suppl 1","key":"10.1016\/j.jpet.2025.103649_bib14","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/ndt\/gft402","article-title":"Aldosterone synthase inhibitors in cardiovascular and renal diseases","volume":"29","author":"Namsolleck","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.jpet.2025.103649_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/1470320317717883","article-title":"LY3045697: Results from two randomized clinical trials of a novel inhibitor of aldosterone synthase","volume":"18","author":"Sloan-Lancaster","year":"2017","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"6","key":"10.1016\/j.jpet.2025.103649_bib16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1161\/CIRCULATIONAHA.123.066314","article-title":"Aldosterone synthase inhibitors and mineralocorticoid receptor antagonists: competitors or collaborators?","volume":"149","author":"Pitt","year":"2024","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.jpet.2025.103649_bib17","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jpet.2025.103649_bib18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"issue":"18","key":"10.1016\/j.jpet.2025.103649_bib19","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jpet.2025.103649_bib20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"9","key":"10.1016\/j.jpet.2025.103649_bib21","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1751-7176.2012.00667.x","article-title":"The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study","volume":"14","author":"Andersen","year":"2012","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"10.1016\/j.jpet.2025.103649_bib22","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.jpet.2025.103649_bib23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing\u2019s disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"10424","key":"10.1016\/j.jpet.2025.103649_bib24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jpet.2025.103649_bib25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.bmcl.2017.12.015","article-title":"Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity","volume":"28","author":"Meyers","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.jpet.2025.103649_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1124\/jpet.116.236463","article-title":"Selectivity of BI 689648, a novel, highly selective aldosterone synthase inhibitor: comparison with FAD286 and LCI699 in nonhuman primates","volume":"359","author":"Weldon","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.jpet.2025.103649_bib27","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/1568026611313120003","article-title":"Progress towards clinically useful aldosterone synthase inhibitors","volume":"13","author":"Cerny","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jpet.2025.103649_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-pharmtox-010814-124302","article-title":"Mineralocorticoids in the heart and vasculature: new insights for old hormones","volume":"55","author":"Lother","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jpet.2025.103649_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jsbmb.2015.08.004","article-title":"Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: utility of monkey as a surrogate for human","volume":"154","author":"Cerny","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"23","key":"10.1016\/j.jpet.2025.103649_bib30","doi-asserted-by":"crossref","first-page":"9382","DOI":"10.1021\/acs.jmedchem.5b01545","article-title":"Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a cortisol-sparing CYP11B2 inhibitor that lowers aldosterone in human subjects","volume":"58","author":"Papillon","year":"2015","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.jpet.2025.103649_bib31","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","article-title":"The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial","volume":"40","author":"Judge","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"1-2","key":"10.1016\/j.jpet.2025.103649_bib32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mce.2003.10.011","article-title":"The regulation of aldosterone synthase expression","volume":"217","author":"Bassett","year":"2004","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103649_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mce.2011.07.034","article-title":"Acute and chronic regulation of aldosterone production","volume":"350","author":"Hattangady","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"10","key":"10.1016\/j.jpet.2025.103649_bib34","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/HJH.0b013e328363570c","article-title":"Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy","volume":"31","author":"Schumacher","year":"2013","journal-title":"J Hypertens"},{"issue":"35","key":"10.1016\/j.jpet.2025.103649_bib35","doi-asserted-by":"crossref","first-page":"12975","DOI":"10.1074\/jbc.RA119.009830","article-title":"Human cytochrome P450 11B2 produces aldosterone by a processive mechanism due to the lactol form of the intermediate 18-hydroxycorticosterone","volume":"294","author":"Reddish","year":"2019","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.jpet.2025.103649_bib36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1210\/me.2012-1287","article-title":"Structural insights into aldosterone synthase substrate specificity and targeted inhibition","volume":"27","author":"Strushkevich","year":"2013","journal-title":"Mol Endocrinol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103649_bib37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1365-2796.1999.00515.x","article-title":"A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?","volume":"246","author":"Andreev","year":"1999","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.jpet.2025.103649_bib38","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000187484","article-title":"Effect of prednisone on renal function in man","volume":"65","author":"van Acker","year":"1993","journal-title":"Nephron"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T22:32:11Z","timestamp":1762209131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525398629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0022356525398629"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103649","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacodynamic effects of highly selective aldosterone synthase inhibitor vicadrostat in cynomolgus monkeys: Contrasting effects of once versus twice daily dosing","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103649","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"103649"}}